Apimeds Pharmaceuticals appoints Sungjoon Chae as Co-CEO

Apimeds Pharmaceuticals US, Inc.

Sungjoon Chae appointed Co-CEO effective May 4, 2026, pursuant to a stockholder nomination.
No family relationships or related party transactions with company officers or directors.
Compensation terms for Chae have not yet been determined; will be disclosed when finalized.
Chae holds a Master of Architecture in Urban Design from Harvard University and specializes in large-scale real estate and urban regeneration.
Existing CEO Dr. Vin Menon continues as CEO; Chae serves as Co-CEO.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.